Volume 11, Issue 3 (Vol.11 No.3 Oct 2022)                   rbmb.net 2022, 11(3): 471-478 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Shalmashi H, Safaei S, Shanehbandi D, Asadi M, Bornehdeli S, Mehdi Navaz A. Evaluation of lncRNA FOXD2-AS1 Expression as a Diagnostic Biomarker in Colorectal Cancer. rbmb.net 2022; 11 (3) :471-478
URL: http://rbmb.net/article-1-935-en.html
Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract:   (1350 Views)
Background: Colorectal cancer (CRC) is still considered one of the prevalent cancers worldwide. Investigation of potential biomarkers for early detection of CRC is essential for the effective management of patients using therapeutic strategies. Considering that, this study was aimed to examine the changes in lncRNA FOXD2-AS1 expression through colorectal tumorigenesis.

Methods: Fifty CRC tumor tissues and fifty adjacent normal tissue samples were prepared and involved in the current study. Total RNA was extracted from the samples and then reverse transcribed to complementary DNA. Next, the expression levels of lncRNA FOXD2-AS1 were evaluated using real-time PCR in CRC samples compared to normal ones. Also, receiver operating characteristic curve analysis was used to evaluate the diagnostic value of FOXD2-AS1 for CRC.

Results: The obtained results showed that the expression level of FOXD2-AS1 gene was significantly (p<0.0001) up-regulated in tumor tissues compared to normal marginal tissues. Also, a significant correlation was observed between higher the expression of FOXD2-AS1and the differentiation of tumor cells. Furthermore, ROC curve analysis estimated an AUC value of 0.59 for FOXD2-AS1, suggesting its potential as a diagnostic target.

Conclusions: Taken together, the current study implied that tissue-specific upregulation of lncRNA FOXD2-AS1 might be appropriate diagnostic biomarkers for CRC. Nonetheless, more studies are needed to validate these results and further illustrate FOXD2-AS1 function through colorectal tumorigenesis.
Full-Text [PDF 272 kb]   (894 Downloads)    
Type of Article: Original Article | Subject: Molecular Biology
Received: 2022/05/2 | Accepted: 2022/06/23 | Published: 2022/12/31

1. Yang X, Duan B, Zhou X. Long non-coding RNA FOXD2-AS1 functions as a tumor promoter in colorectal cancer by regulating EMT and Notch signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21(16):3586-91.
2. Ahmadi A, Bayatiani MR, Seif F, Ansari J, Rashidi P, Moghadasi M, et al. Evaluation of Radiotherapy on miR-374 Gene Expression in Colorectal Cancer Patient Blood Samples. Rep Biochem Mol Biol. 2022;10(4):614. [DOI:10.52547/rbmb.10.4.614] [PMID] [PMCID]
3. Corbo C, Cevenini A, Salvatore F. Biomarker discovery by proteomics‐based approaches for early detection and personalized medicine in colorectal cancer. Proteomics Clin Appl. 2017;11(5-6):1600072. [DOI:10.1002/prca.201600072] [PMID]
4. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145-164. [DOI:10.3322/caac.21601] [PMID]
5. Yang Z, Sun Y, Liu R, Shi Y, Ding S. Plasma long noncoding RNAs PANDAR, FOXD2-AS1, and SMARCC2 as potential novel diagnostic biomarkers for gastric cancer. Cancer Manag Res. 2019;11:6175-6184. [DOI:10.2147/CMAR.S201935] [PMID] [PMCID]
6. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol cell. 2011;43(6):904-14. [DOI:10.1016/j.molcel.2011.08.018] [PMID] [PMCID]
7. Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol. 2011 Jun;21(6):354-61. [DOI:10.1016/j.tcb.2011.04.001] [PMID]
8. An Q, Zhou L, Xu N. Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143. Biomed Pharmacother. 2018;103:415-420. [DOI:10.1016/j.biopha.2018.03.138] [PMID]
9. Bian Z, Zhang J, Li M, Feng Y, Wang X, Zhang J, et al. LncRNA-FEZF1-AS1 promotes tumor proliferation and metastasis in colorectal cancer by regulating PKM2 signaling. Clin Cancer Res. 2018;24(19):4808-4819. [DOI:10.1158/1078-0432.CCR-17-2967] [PMID]
10. Li Z, Hou P, Fan D, Dong M, Ma M, Li H, et al. The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer. Cell Death Differ. 2017;24(1):59-71. [DOI:10.1038/cdd.2016.95] [PMID] [PMCID]
11. Liu H, Deng H, Zhao Y, Li C, Liang Y. LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling. J Exp Clin Cancer Res. 2018;37(1):279. [DOI:10.1186/s13046-018-0950-9] [PMID] [PMCID]
12. Chen G, Sun W, Hua X, Zeng W, Yang L. Long non-coding RNA FOXD2-AS1 aggravates nasopharyngeal carcinoma carcinogenesis by modulating miR-363-5p/S100A1 pathway. Gene. 2018;645:76-84. [DOI:10.1016/j.gene.2017.12.026] [PMID]
13. Chang Y, Zhang J, Zhou C, Qiu G, Wang G, Wang S, et al. Long non-coding RNA FOXD2-AS1 plays an oncogenic role in hepatocellular carcinoma by targeting miR‑206. Oncol Rep. 2018;40(6):3625-34. [DOI:10.3892/or.2018.6752] [PMID]
14. Chen Z, Zhang Z, Zhao D, Feng W, Meng F, Han S, et al. Long noncoding RNA (lncRNA) FOXD2-AS1 promotes cell proliferation and metastasis in hepatocellular carcinoma by regulating MiR-185/AKT axis. Med Sci Monit. 2019;25:9618-9629. [DOI:10.12659/MSM.918230] [PMID] [PMCID]
15. Hu W, Feng H, Xu X, Huang X, Huang X, Chen W, et al. Long noncoding RNA FOXD2‐AS1 aggravates hepatocellular carcinoma tumorigenesis by regulating the miR‐206/MAP3K1 axis. Cancer med. 2020;9(15):5620-31. [DOI:10.1002/cam4.3204] [PMID] [PMCID]
16. Lei T, Zhu X, Zhu K, Jia F, Li S. EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway. Cancer Biol Ther. 2019;20(7):1007-1016. [DOI:10.1080/15384047.2019.1595276] [PMID] [PMCID]
17. Xu Tp, Wang WY, Ma P, Shuai Y, Zhao K, Wang YF, et al. Upregulation of the long noncoding RNA FOXD2-AS1 promotes carcinogenesis by epigenetically silencing EphB3 through EZH2 and LSD1, and predicts poor prognosis in gastric cancer. Oncogene. 2018;37(36):5020-36. [DOI:10.1038/s41388-018-0308-y] [PMID]
18. Zhang M, Jiang X, Jiang S, Guo Z, Zhou Q, He J. LncRNA FOXD2-AS1 regulates miR-25-3p/Sema4c axis to promote the invasion and migration of colorectal cancer cells. Cancer Manag Res. 2019;11:10633-39. [DOI:10.2147/CMAR.S228628] [PMID] [PMCID]
19. Ge P, Cao L, Yao Y-J, Jing R-J, Wang W, Li H-J. lncRNA FOXD2-AS1 confers cisplatin resistance of non-small-cell lung cancer via regulation of miR185-5p-SIX1 axis. Onco Targets Ther. 2019;12:6105-17. [DOI:10.2147/OTT.S197454] [PMID] [PMCID]
20. Rong L, Zhao R, Lu J. Highly expressed long non-coding RNA FOXD2-AS1 promotes non-small cell lung cancer progression via Wnt/β-catenin signaling. Biochem Biophys Res Commun. 2017;484(3):586-91. [DOI:10.1016/j.bbrc.2017.01.141] [PMID]
21. Liu H, Zhang J, Luo X, Zeng M, Xu L, Zhang Q, et al. Overexpression of the long noncoding RNA FOXD2-AS1 promotes cisplatin resistance in esophageal squamous cell carcinoma through the miR-195/Akt/mTOR axis. Oncology research. 2020;28(1):65. [DOI:10.3727/096504019X15656904013079] [PMID] [PMCID]
22. Shi W, Gao Z, Song J, Wang W. Silence of FOXD2-AS1 inhibited the proliferation and invasion of esophagus cells by regulating miR-145-5p/CDK6 axis. Histol Histopathol. 2020 Sep;35(9):1013-21.
23. Jiang M, Qiu N, Xia H, Liang H, Li H, Ao X. Long non‑coding RNA FOXD2‑AS1/miR‑150‑5p/PFN2 axis regulates breast cancer malignancy and tumorigenesis. Int J Oncol. 2019;54(3):1043-1052. [DOI:10.3892/ijo.2019.4671] [PMID]
24. Shen F, Chang H, Gao G, Zhang B, Li X, Jin B. Long noncoding RNA FOXD2‐AS1 promotes glioma malignancy and tumorigenesis via targeting miR‐185‐5p/CCND2 axis. J Cell Biochem. 2019;120(6):9324-9336. [DOI:10.1002/jcb.28208] [PMID]
25. Zhao Q, Ying J, Jing J, Wang S. LncRNA FOXD2-AS1 stimulates glioma progression through inhibiting P53. Eur Rev Med Pharmacol Sci. 2020;24:4382-8.
26. Zhou L, Li Z, Shao X, Yang B, Feng J, Xu L, et al. Prognostic value of long non-coding RNA FOXD2-AS1 expression in patients with solid tumors. Pathol Res Pract. 2019;215(9):152449. [DOI:10.1016/j.prp.2019.152449] [PMID]
27. Su F, He W, Chen C, Liu M, Liu H, Xue F, et al. The long non-coding RNA FOXD2-AS1 promotes bladder cancer progression and recurrence through a positive feedback loop with Akt and E2F1. Cell Death Dis. 2018;9(233):1-17. [DOI:10.1038/s41419-018-0275-9] [PMID] [PMCID]
28. Bayatiani MR, Ahmadi A, Aghabozorgi R, Seif F. Concomitant Up-Regulation of Hsa-Mir-374 and Down-Regulation of Its Targets, GSK-3β and APC, in Tissue Samples of Colorectal Cancer. Rep Biochem Mol Biol. 2021;9(4):408-416. [DOI:10.52547/rbmb.9.4.408] [PMID] [PMCID]
29. Kim BH, Kim JM, Kang GH, Chang HJ, Kang DW, Kim JH, et al. Standardized Pathology Report for Colorectal Cancer, 2nd Edition. Pathol Transl Med. 2020;54(1):1-19. [DOI:10.4132/jptm.2019.09.28] [PMID] [PMCID]
30. Zhou S, Wang J, Zhang Z. An emerging understanding of long noncoding RNAs in kidney cancer. J Cancer Res Clin Oncol. 2014;140(12):1989-95. [DOI:10.1007/s00432-014-1699-y] [PMID]
31. Dong H, Cao W, Xue J. Long noncoding FOXD2-AS1 is activated by CREB1 and promotes cell proliferation and metastasis in glioma by sponging miR-185 through targeting AKT1. Biochem Biophys Res Commun. 2019;508(4):1074-81. [DOI:10.1016/j.bbrc.2018.12.050] [PMID]
32. Yu M, Song XG, Zhao YJ, Dong XH, Niu LM, Zhang ZJ, et al. Circulating Serum Exosomal Long Non-Coding RNAs FOXD2-AS1, NRIR, and XLOC_009459 as Diagnostic Biomarkers for Colorectal Cancer. Front Oncol. 2021;11:618967. [DOI:10.3389/fonc.2021.618967] [PMID] [PMCID]
33. Guo F, Guo R, Zhang L. Downregulation of lncRNA FOXD2-AS1 Confers Radiosensitivity to Gastric Cancer Cells via miR-1913/SETD1A Axis. Cytogenet Genome Res. 2022:162(1-2):10-27. [DOI:10.1159/000522653] [PMID]
34. Li H, Han Q, Chen Y, Chen X, Ma R, Chang Q, et al. Upregulation of the long non-coding RNA FOXD2-AS1 is correlated with tumor progression and metastasis in papillary thyroid cancer. Am J Transl Res. 2019;11(9):5457-71.
35. Bao J, Zhou C, Zhang J, Mo J, Ye Q, He J, Diao J. Upregulation of the long noncoding RNA FOXD2-AS1 predicts poor prognosis in esophageal squamous cell carcinoma. Cancer Biomark. 2018;21(3):527-533. [DOI:10.3233/CBM-170260] [PMID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2015 All Rights Reserved | Reports of Biochemistry and Molecular Biology

Designed & Developed by : Yektaweb